Norgen Biotek Corp. Achieves ISO 13485:2003 and ISO 9001:2008 Certification

04-Nov-2009 - Canada

Norgen Biotek Corp. announced successful certification to ISO 13485:2003 and ISO 9001:2008. ISO 13485 and ISO 9001 are world-recognized quality management system standards, with ISO 13485 specifically pertaining to the requirements for a comprehensive management system for the design and manufacture of medical devices. The quality system was audited by BSI Management Systems Inc, one of the foremost auditing bodies in the world.

“We are dedicated to providing our customers with first class sample preparation kits for RNA, microRNA, DNA and protein purification, clean-up and concentration and to provide dedicated and expert support services to our customers and partners worldwide” said Dr. Yousef Haj-Ahmad, President & CEO. “And now with the ISO certification we can transition our first in class kits into diagnostics. The sensitivity and specificity of the diagnostic kit is highly dependent on sample preparation, therefore we are in an excellent position to make this successful transition” said Dr. Yousef Haj-Ahmad, President & CEO of Norgen Biotek.

Other news from the department politics & laws

Most read news

More news from our other portals

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.